Tag: Fouad Namouni
BMS, Compugen to trial COM701 Opdivo combo in advanced solid tumors
US biopharma company Bristol-Myers Squibb (BMS) has entered into a clinical collaboration with Compugen to evaluate the combination of its cancer drug Opdivo (nivolumab) with ... Read More